ES2492673T3 - Formas cristalinas de un ingrediente farmacéutico activo - Google Patents

Formas cristalinas de un ingrediente farmacéutico activo Download PDF

Info

Publication number
ES2492673T3
ES2492673T3 ES10196836.0T ES10196836T ES2492673T3 ES 2492673 T3 ES2492673 T3 ES 2492673T3 ES 10196836 T ES10196836 T ES 10196836T ES 2492673 T3 ES2492673 T3 ES 2492673T3
Authority
ES
Spain
Prior art keywords
active pharmaceutical
pharmaceutical ingredient
crystal forms
silodosin
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10196836.0T
Other languages
English (en)
Inventor
Arthur Pichler
Andreas Hotter
Clemens Häfele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of ES2492673T3 publication Critical patent/ES2492673T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La forma cristalina δ de Silodosina que tiene un patrón de difracción de rayos X de polvo que comprende los picos en ángulos 2-theta de 6,6 ± 0,2°, 10,5 ± 0,2°, 13,1 ± 0,2°, 21,3 ± 0,2º y 22,8 ± 0,2°.
ES10196836.0T 2010-12-23 2010-12-23 Formas cristalinas de un ingrediente farmacéutico activo Active ES2492673T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10196836.0A EP2474529B1 (en) 2010-12-23 2010-12-23 Crystalline forms of an active pharmaceutical ingredient

Publications (1)

Publication Number Publication Date
ES2492673T3 true ES2492673T3 (es) 2014-09-10

Family

ID=43734023

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10196836.0T Active ES2492673T3 (es) 2010-12-23 2010-12-23 Formas cristalinas de un ingrediente farmacéutico activo

Country Status (5)

Country Link
EP (1) EP2474529B1 (es)
JP (1) JP5847567B2 (es)
ES (1) ES2492673T3 (es)
PL (1) PL2474529T3 (es)
SI (1) SI2474529T1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
JP2016147811A (ja) * 2015-02-10 2016-08-18 ダイト株式会社 シロドシンγ型結晶の製造方法
CN109824569B (zh) * 2019-04-04 2022-09-20 重庆医药高等专科学校 一种西罗多辛晶型i及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9225348D0 (en) 1992-12-03 1993-01-27 Pilkington Plc Bridged photochromics
UA78854C2 (en) 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
BR0317349A (pt) 2002-12-16 2005-11-16 Kissei Pharmaceutical Droga sólida para uso oral

Also Published As

Publication number Publication date
SI2474529T1 (sl) 2014-12-31
PL2474529T3 (pl) 2014-10-31
EP2474529B1 (en) 2014-05-14
JP5847567B2 (ja) 2016-01-27
JP2012131786A (ja) 2012-07-12
EP2474529A1 (en) 2012-07-11

Similar Documents

Publication Publication Date Title
MY163083A (en) Solid forms of a pharmaceutically active substance
SMT201400126B (it) Uso di amisulpride per il trattamento di nausea e vomito post-operatori
UY31698A (es) Preparacion solida de desintegracion oral
PE20140698A1 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2, 4-diamina
CR20110457A (es) Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma
AR088755A1 (es) Formas solidas de un inhibidor de disociacion transtiretina
BRPI0821087A2 (pt) Preparação externa para a pele.
CA141113S (en) Dispenser for pharmaceutical powder formulations
EP2736837A4 (en) ACTIVE MATERIALS FOR A NANOSTRUCTURED BATTERY AND METHOD FOR THE PRODUCTION THEREOF
USD650833S1 (en) Typeface
DK2462116T3 (da) Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser
BR112015002767A2 (pt) composições, métodos, e sistemas para a síntese e uso de agentes de imagiologia
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
PL2808325T3 (pl) Podstawione azole, przeciwwirusowy składnik czynny, kompozycja farmaceutyczna, sposób ich wytwarzania i stosowania
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
MX353024B (es) Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
EP2680318A4 (en) SEALING FILM FOR A SOLAR CELL AND SOLAR CELL THEREWITH
UY33348A (es) Compuestos de furopiridina y usos de los mismos
EP2717362A4 (en) ACTIVE MATERIAL FOR SECONDARY BATTERIES AND SECONDARY BATTERY THEREWITH
BR112014009297A2 (pt) processos para a preparação de 6-cloro-2,3,4,9-tetrahidro-1 h-carbazol-1-carboxamida e dos seus precursores
WO2013114053A3 (fr) Composition pharmaceutique a liberation prolongee de trimetazidine.
ES2492673T3 (es) Formas cristalinas de un ingrediente farmacéutico activo
AR091186A1 (es) Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamida
AR082435A1 (es) Valsartan altamente cristalino